PharmiWeb.com: The Heart of Life Sciences on the Web
WEBPharmiWeb Today Story. Basel, 10 September 2024 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today the opening of its new Pharma Research and Early Development (pRED) Center at its global headquarters in Basel, Switzerland. Equipped with cutting-edge technologies and housing around 1,000 state-of-the-art laboratory and office workplaces, the ...
Top Ten Pharmaceutical Companies in Australia - PharmiWeb.com
WEBAug 3, 2021 · Here are ten of the top pharmaceutical companies in the country as of 2021…. Pfizer. Pfizer has manufacturing sites in Sydney, Melbourne, Perth and Adelaide, and its products are used in hospitals and pharmacies across the country. Pfizer Australia offers a portfolio containing some of the world’s …
PharmaLex expands global footprint capabilities for clinical and ...
WEBJan 26, 2022 · PharmaLex expands global footprint capabilities for clinical and regulatory services with Phlexglobal merger Merger continues commitment to innovation and strengthens tech-enablement and automation Frankfurt, Germany – 25 January 2022: PharmaLex Group, a leading provider of s...
ProductLife Group Acquires Axpharma in Response to Accelerating …
WEBOct 13, 2020 · The strategic acquisition is part of the Group’s aim to widen its expertise and global reach as the pandemic forces renewed focus on safety, quality and speed to marketParis, France – October 6th, 2020 — ProductLife Group (PLG), a specialist provider of regulatory and compliance services for...
Microneedle Patch Technologies: Innovations in Drug Delivery
WEBNov 16, 2023 · Phase-transition microneedle patches are designed to deliver drugs in a controlled and sustained manner. These patches consist of a matrix of solid microneedles embedded within a temperature-sensitive material. Upon application to the skin, the microneedles dissolve, releasing the drug payload in response to the skin's temperature.
Top Pharmaceutical Companies in the United States
WEBOct 21, 2021 · Founded over 170 years ago, Pfizer is one of the world’s premier biopharmaceutical companies, with a global portfolio covering medicines, vaccines, and some of the world’s best-known consumer health care products. With headquarters in New York, the company has over 78,000 employees globally, and in 2020, total revenues reached $41.9 billion.
New hydrogel injection for knee osteoarthritis offers patients a …
WEBSep 30, 2021 · SAFE AND SUSTAINED PAIN RELIEF WITH A SINGLE INJECTION. A novel injectable treatment for knee osteoarthritis that harnesses non-biodegradable hydrogel technology - Arthrosamid ® - was officially launched to the UK market at the British Orthopaedic Association (BOA) Annual Congress, 21 st-24 th September 2021. Pioneered by Contura Ineternational Ltd, [international manufacturers of therapeutic ...
UCB announces European Commission approval of ZILBRYSQ® …
WEBDec 4, 2023 · UCB announces European Commission approval of ZILBRYSQ ® (zilucoplan) for the treatment of adults with generalized Myasthenia Gravis. European approval of ZILBRYSQ ® (zilucoplan) granted as an add-on to standard therapy for the treatment of generalized Myasthenia Gravis (gMG) in adult patients who are anti-acetylcholine receptor (AChR) antibody-positive1
US FDA approves Jardiance® for the treatment of adults with …
WEBSep 25, 2023 · Approval adds to the treatment options for the more than 35 million adults in the U.S. affected by chronic kidney disease (CKD) Jardiance ® (empagliflozin) 10 mg tablets significantly reduced the risk of kidney disease progression and cardiovascular death in adults with CKD, as established in the EMPA-KIDNEY phase III trial; EMPA-KIDNEY is the first SGLT2 inhibitor CKD trial to demonstrate a ...
Editor Details - PharmiWeb.com
WEBDec 8, 2023 · With 5.6 months of additional follow-up and 78.3% of patients having completed Kisqali ® (ribociclib) investigational treatment, the updated analysis shows sustained iDFS benefit and stability in secondary endpoints including overall survival (OS) 1,2; iDFS benefit remains consistent across key patient subgroups; among patients with stage II and stage III tumors, Kisqali lowered risk by 30% ...